Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 1 Apr 2020 |
| Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | 1 Apr 2020 |
| Genmab A/S has published its Articles of Association | 31 Mar 2020 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 31 Mar 2020 |
| Genmab Files Annual Report with the U.S. Securities and Exchange Commission | 30 Mar 2020 |
| Passing of Genmab A/S’ Annual General Meeting | 26 Mar 2020 |